David Draney, DO
Psychiatry · Searcy, ARNPI 1891141644
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.2% of the total across 478 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 24 manufacturers reported payments, led by AbbVie at 29.1% of the total. Among psychiatry clinicians in AR with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 478 payments — averaging $17.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Otsuka America Pharmaceutical, Inc.$1K
- Johnson & Johnson$764
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$740
- Alkermes, Inc.$645
- Neurocrine Biosciences, Inc.$625
- plus $2K from 18 others
What the payments were for
- Food & beverage$8,42798%
- Education$1542%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 127 | $2,500 |
| Otsuka America Pharmaceutical, Inc. | 71 | $1,042 |
| Johnson & Johnson | 46 | $764 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 40 | $740 |
| Alkermes, Inc. | 39 | $645 |
| Neurocrine Biosciences, Inc. | 32 | $625 |
| Teva Pharmaceuticals USA, Inc. | 30 | $531 |
| Lundbeck LLC | 16 | $263 |
| Supernus Pharmaceuticals, Inc. | 10 | $262 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $227 |
| Tris Pharma Inc | 10 | $200 |
| Vanda Pharmaceuticals Inc. | 8 | $139 |
| Axsome Therapeutics, Inc. | 6 | $130 |
| Shire North American Group Inc | 6 | $87 |
| Eisai Inc. | 5 | $77 |
| E.r. Squibb & Sons, L.L.C. | 3 | $71 |
| Ironshore Pharmaceuticals Inc. | 3 | $64 |
| Sun Pharmaceutical Industries Inc. | 3 | $58 |
| Avanir Pharmaceuticals, Inc. | 3 | $48 |
| Sunovion Pharmaceuticals Inc. | 3 | $44 |
| Corium, LLC | 1 | $23 |
| Collegium Pharmaceutical, Inc. | 1 | $17 |
| Acadia Pharmaceuticals Inc | 1 | $12 |
| Idorsia Pharmaceuticals US Inc | 1 | $12 |
How this compares
$8,581 in reported general payments places this provider in the 90th percentile of 235 psychiatry providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 14 | $52,727 |
| Lurasidone Hcl | 23 | $14,080 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 140 | $5,208 |
| Paliperidone ErPaliperidone | 20 | $4,307 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 33 | $2,004 |
| Atomoxetine Hcl | 24 | $1,605 |
| Methylphenidate Hcl | 48 | $1,382 |
| Gabapentin | 53 | $976 |
| Doxepin Hcl | 13 | $765 |
| Prazosin Hcl | 35 | $758 |
| Clozapine | 12 | $692 |
| Buspirone Hcl | 41 | $622 |
| Quetiapine Fumarate | 38 | $502 |
| Duloxetine Hcl | 27 | $449 |
| Aripiprazole | 24 | $434 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna | $764 | $52,72714 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 235 psychiatry providers in Arkansas.
Other psychiatry in Searcy
- Ronald WautersSearcy$204K
- Herman ClementsSearcy$187K
- Robert StrayhanSearcy$6K
- Brian HowardSearcy$4K
- Jacqueline KoichiSearcy$3K
- Christopher LewisSearcy$1K
- Leslie SmithLittle Rock$766K
- Tad TillemansLittle Rock$656K
- Steven KoryElm Springs$628K
- Randal ScholmaLowell$111K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.